Interestingly, despite the stimulatory effect of CD80 binding to CD28 [8], it was found that deactivating CD80 reduces tumour growth and increases susceptibility to anti-CTLA-4 antibody treatment [36]. The gene discussed is CD28; the disease is neoplasm.